ストックスクリーナーアプリを入手
4.66
2.10%
-0.10
アフターアワーズ：
4.69
0.03
+0.64%
前日終値:
$4.76
開ける：
$4.81
24時間の取引高:
144.35K
Relative Volume:
0.49
時価総額：
$193.84M
収益：
$2.00M
当期純損益:
$109.16M
株価収益率:
1.8038
EPS:
2.5835
ネットキャッシュフロー:
$-9.11M
1週間 パフォーマンス:
-6.99%
1か月 パフォーマンス:
+9.65%
6か月 パフォーマンス:
+37.06%
1年 パフォーマンス:
+91.77%
1日の値動き範囲:
$4.65
$4.82
1週間の範囲:
$4.65
$5.01
52週間の値動き範囲:
$2.09
$5.47
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
名前
Oramed Pharmaceuticals Inc
セクター
電話
646-844-1164
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.66 | 193.84M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-12 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-09 | 開始されました | National Securities | Buy |
| 2020-12-03 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-11 | 開始されました | Aegis Capital | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-12-11 | 再開されました | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 繰り返されました | FBR Capital | Outperform |
| 2015-12-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-11-19 | 開始されました | FBR Capital | Outperform |
| 2015-04-13 | 再開されました | MLV & Co | Buy |
| 2014-01-30 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-08 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-08 | 開始されました | MLV & Co | Buy |
| 2013-12-03 | 開始されました | Aegis Capital | Buy |
すべてを表示
Oramed Pharmaceuticals Inc (ORMP) 最新ニュース
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - Yahoo Finance
MSN Money - MSN
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView
Oramed: Q2 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView
Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Oramed Pharmaceuticals (ORMP) Holds Steady at $4.33 as Range-Bound Trading PersistsSpring Pattern - dars.gov.et
ORMP | Oramed Pharmaceuticals Inc. Executive Compensation - Quiver Quantitative
ORMP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals announces annual shareholder meeting - Bitget
ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) | ORMP ARS - Stock Titan
Oral Biologics Drugs Companies at 22.65% CAGR By 2034 - Fortune Business Insights
Oramed Pharmaceuticals Market Sentiment - Benzinga
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Balance Sheet - TradingKey
ORMP Q4 2025 Earnings: EPS Surges Past Estimates Despite Revenue Absence, Stock Declines 3.13%Earnings Forecast Report - dars.gov.et
ORMP|Oramed Pharmaceuticals Inc|Price:4.762|Chg%:+0.192 - TradingKey
Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP - TradingView
TradingKey - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed Pharmaceuticals Inc (OJU1.SG) stock price, news, quote and history - Yahoo Finance UK
Nano Dimension Ltd. (NASDAQ: NNDM) sees Oramed stake drop to 3.3% - Stock Titan
AlTi Global Leads Our Selection Of 3 Promising Penny Stocks - simplywall.st
Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback - Ad-hoc-news.de
Oramed Pharmaceuticals Q4 2025 Earnings: EPS Surprise Driven by Non-Operating Gains; Stock Slips Despite BeatLong-Term Guidance - vinanet.vn
Oramed Pharmaceuticals Inc. Net Worth (2026) - GuruFocus
Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals Inc (ORMP) 財務データ
収益
当期純利益
現金流量
EPS
Oramed Pharmaceuticals Inc (ORMP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO |
Jul 01 '26 |
Sale |
4.46 |
137,000 |
611,431 |
1,023,384 |
| Gabay Avraham | Chief Financial Officer |
Jul 01 '26 |
Sale |
4.51 |
73,360 |
330,744 |
671,785 |
0.24%
1.67%
大文字化:
|
ボリューム (24 時間):